HOME >> BIOLOGY >> NEWS
Diabetes drug may be new tool in treating breast cancer

Washington, D.C Researchers at Georgetown University's Lombardi Comprehensive Cancer Center have decoded the step-by-step process by which a class of popular anti-diabetes drugs inhibits cancerous tumor growth. With the discovery of this molecular chain of events, as reported in the September 2003 issue of Molecular and Cellular Biology, the Georgetown researchers are now studying whether these anti-diabetes drugs, called glitazones, could one day be effective anti-cancer drugs.

Glitazones are taken by more than two million people with Type 2 diabetes. They are marketed under the names AvandiaTM and ActosTM, by SmithKline Beecham and Eli Lilly, respectively. Glitazones bind to a particular target on a cell, and in diabetics, they work by reducing insulin resistance at the sites of insulin action in the muscle and liver. Previous studies have also shown that glitazones also have the ability to inhibit tumor growth. However, until this study no one understood how this process worked.

"This study shows for the first time a direct link between a gene causing breast and other cancers and a gene linked to diabetes and the production of fat cells," said Richard Pestell, M.D., PhD, director of Lombardi Comprehensive Cancer Center. "The link between these cellular components may be a lynchpin in some cancers linking some cancers and metabolism directly. Potentially, we could be on the way to finding new therapeutic leads that would improve both diseases."

Pestell and his colleagues describe a complex relationship between a cancer causing gene, Cyclin D1, and a cancer-blocking receptor called PPAR gamma, which is involved in fat cell development. They are respectively found in breast cancer tissue and normal breast tissue. When PPAR is "turned on" by glitazones, tumor growth is inhibited. Conversely, when Cyclin D1 is activated in cells, it causes cancer cells to divide uncontrollably and excessively. <
'"/>

Contact: Elizabeth McDonald
eem6@georgetown.edu
202-687-5100
Georgetown University Medical Center
15-Sep-2003


Page: 1 2

Related biology news :

1. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
2. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
3. Joslin Diabetes Center launches research section on developmental and stem cell biology
4. Joslin Diabetes Center releases new low impact exercise video
5. As obesity skyrockets, Joslin Diabetes Center urges action to stem the tide of type 2 diabetes
6. Diabetes in the elderly linked to fewer cellular power plants
7. Diabetes therapies and liquid memory may develop from micro fluid research, Science researchers say
8. Diabetes tied to altering of the hearts circadian clock
9. Bacteria From Gum Infections Associated With Diabetes, Chronic Lung Disease, UB Studies Find
10. New Findings On Receptor Regulation May Lead To Better Drugs For Diabetes
11. Researchers Identify And Isolate First Gene For A Form Of Insulin-Dependent Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... JOSE, Calif. (PRWEB) , ... ... ... LLC. announced significant workflow advances to the ImageXpress® Pico Automated Cell Imaging ... cell scoring. , The Digital Confocal option allows scientists to ...
(Date:10/26/2019)... ... October 24, 2019 , ... World Cord Blood Day (WCBD) takes place ... midwives to learn about the current and future uses of cord blood stem cells, ... being used to treat and cure over 80 different life-threatening diseases, including leukemia, lymphoma, ...
(Date:10/26/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... October ... ... the world’s premier manufacturer of custom built, helium-based leak testing instruments for the ... launch of its newest and most advanced helium leak detection system, the ...
Breaking Biology News(10 mins):
(Date:11/5/2019)... SOMERSET, N.J. (PRWEB) , ... ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... of its next-generation cell line development technology, GPEx® Boost. The technology enhances ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, a breakthrough ... drug360 brings tellic’s expertise in biomedical language processing and machine learning to ... relationships between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and ...
(Date:10/29/2019)... (PRWEB) , ... October 29, 2019 , ... ... signature of the skin*. Using Silios CMS-C multispectral imagers , researchers identified ... approach can replace identification based on retinal imaging, face recognition, fingerprints and vasculature. ...
(Date:10/22/2019)... ... October 22, 2019 , ... ... announced that its lead program, DBI-001, met its primary safety endpoints, with no ... phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). ...
Breaking Biology Technology:
Cached News: